260 related articles for article (PubMed ID: 30710685)
1. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
Yan F; Lu N; Gu Z; Huang W; Wang S; Gao X; Dou L; Li F; Wang L; Li M; Liu D; Gao C
Ann Hematol; 2022 Feb; 101(2):397-408. PubMed ID: 34735613
[TBL] [Abstract][Full Text] [Related]
8. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia.
Gao F; Zhou X; Shi J; Luo Y; Tan Y; Fu H; Lai X; Yu J; Huang H; Zhao Y
Ann Hematol; 2020 Nov; 99(11):2679-2687. PubMed ID: 32519094
[TBL] [Abstract][Full Text] [Related]
11. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
12. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
[No Abstract] [Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
[TBL] [Abstract][Full Text] [Related]
16. Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial.
Wen B; Zhang X; Chen S; Fan J; Yang S; Cai Y; Wang P; Zhang Q; Gu Q; Du X
Hematol Oncol; 2022 Oct; 40(4):777-786. PubMed ID: 35554955
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
Ahmed S; Bashir Q; Bassett RL; Ullah F; Aung F; Valdez BC; Alousi AM; Hosing C; Kebriaei P; Khouri I; Marin D; Nieto Y; Olson A; Oran B; Qazilbash MH; Rezvani K; Mehta R; Shpall EJ; Ciurea S; Andersson BS; Champlin RE; Popat UR
Am J Hematol; 2024 Apr; 99(4):562-569. PubMed ID: 38314663
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
[TBL] [Abstract][Full Text] [Related]
19. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
[TBL] [Abstract][Full Text] [Related]
20. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
Huan Ng C; Jang-Milligan F; Schultz KR
Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
